Bioorganic and Medicinal Chemistry Letters p. 3652 - 3657 (2018)
Update date:2022-07-31
Topics:
Ashraf-Uz-Zaman, Md
Sajib, Md Sanaullah
Cucullo, Luca
Mikelis, Constantinos M.
German, Nadezhda A.
Several recent reports have highlighted the feasibility of the use of penfluridol, a well-known antipsychotic agent, as a chemotherapeutic agent. In vivo experiments have confirmed the cytotoxic activity of penfluridol in triple-negative breast cancer model, lung cancer model, and further studies have been proposed to assess its anticancer activity and viability for the treatment of glioblastomas. However, penfluridol anticancer activity was observed at a dosage significantly higher than that administered in antipsychotic therapy, thus raising the concern for the potential onset of CNS side effects in patients undergoing intensive pharmacological treatment. In this study, we evaluate the potential CNS toxicity of penfluridol side by side with a set of analogs.
View MoreContact:+86-(0)21-3770 9035
Address:Room 301, Building 2, Meijiabang Road 1508, Shanghai China
Nanjing Habo Medical Technology Co., Ltd.
Contact:025-85769882
Address:No.108. Ganjiabian east. Qixia District .Nanjing
Taixing Shenfeng Chemical Co., Ltd.
Contact:+86-523-87117033, 87117666
Address:4# Yinsanlu, Huangqiao town, Taixing, Jiangsu, China.
Jiangxi Dongxu Chemical Science & Technology Co.,Ltd
Contact:+86-791-86899381
Address:Nanchang, Jiangxi, China
Contact:+1-416-493-6870
Address:Toronto, Canada
Doi:10.1002/zaac.201000228
(2011)Doi:10.1021/ja00167a096
(1990)Doi:10.1021/ol1030316
(2011)Doi:10.1021/ja200089f
(2011)Doi:10.1007/BF00962133
(1989)Doi:10.1080/10426501003767110
(2011)